Financial Partners Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Financial Partners Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$9.65M	Sell	73,514 -1,708	-2%	-$221K	2.15%	14
2022 Q3	$8.8M	Sell	75,222 -975	-1%	-$121K	2.08%	18
2022 Q2	$8.96M	Buy	76,197 +185	+0.2%	+$22K	1.93%	19
2022 Q1	$9.9M	Sell	76,012 -53	-0.1%	-$6.9K	1.84%	22
2021 Q4	$11.6M	Buy	76,065 +2,397	+3%	+$371K	2.06%	17
2021 Q3	$11.9M	Sell	73,668 -720	-1%	-$121K	2.18%	16
2021 Q2	$12.2M	Sell	74,388 -846	-1%	-$130K	2.24%	17
2021 Q1	$11.3M	Sell	75,234 -270	-0.4%	-$42.9K	2.29%	15
2020 Q4	$11.4M	Sell	75,504 -825	-1%	-$118K	2.61%	15
2020 Q3	$10.3M	Sell	76,329 -1,200	-2%	-$163K	2.75%	12
2020 Q2	$10.6M	Buy	77,529 +149	+0.2%	+$19K	3.05%	11
2020 Q1	$8.34M	Buy	+77,380	New	+$8.91M	2.66%	11
2018 Q4	$6.99M	Buy	72,510 +26,345	+57%	+$2.8M	2.3%	20
2018 Q3	$5.63M	Buy	+46,165	New	+$5.44M	1.6%	29
2017 Q1	–	Sell	-17,145	Closed	-$1.52M	–	112
2016 Q4	$1.52M	Buy	+17,145	New	+$1.56M	0.36%	60

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CANY

Caxton Associates (New York) New York $3.18B AUM 54.49% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Financial Partners Capital Management's IBB Position: Q4 2022 in Review

Financial Partners Capital Management reduced its iShares Biotechnology ETF (IBB) stake by 2.3% in Q4 2022, selling an estimated $221K and leaving 73,514 shares worth $9.65M. The position accounts for 2.15% of the portfolio, ranked #14.

Financial Partners Capital Management first reported a position in IBB in Q4 2016 and has held it in 15 quarters since. The position peaked at $12.2M in Q2 2021. 902 funds tracked by Wall St. Rank hold IBB as of Q4 2022.

Financial Partners Capital Management held 73,514 shares of iShares Biotechnology ETF worth $9.65M as of Q4 2022.
Financial Partners Capital Management sold 1,708 iShares Biotechnology ETF shares in Q4 2022, an estimated $221K.
iShares Biotechnology ETF made up 2.15% of Financial Partners Capital Management's portfolio in Q4 2022, its #14 holding.
Financial Partners Capital Management first reported a position in iShares Biotechnology ETF in Q4 2016 and has held it in 15 quarters since.
Financial Partners Capital Management's iShares Biotechnology ETF position peaked at $12.2M in Q2 2021.
902 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2022.

Based on Financial Partners Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.